TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
PRQR

ProQR Therapeutics BV

Healthcare · Biotechnology

1.70$ +0.0% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns ProQR Therapeutics BV (PRQR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 64.8% of the shares are freely tradable; institutional investors hold 42.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 42.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 18.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 64.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 141Mio.

Largest Shareholders

Institutions

Institutions PRQR
Name Stake (%) Shares Change (%) Date
Adage Capital Partners Gp LLC 6.39 9,015,897 +44.2 06/30/2026
Aberdeen Group PLC 6.33 8,932,507 +169.3 06/30/2026
Affinity Asset Advisors, LLC 3.93 5,543,936 +125.9 06/30/2026
Privium Fund Management B.V. 3.87 5,467,149 +2.0 03/31/2026
Kynam Capital Management, LP 1.11 1,566,317 +0.0 06/30/2026
Dafna Capital Management LLC 1.08 1,530,361 -2.4 06/30/2026
Squadron Capital Management LLC 1.07 1,511,496 +0.0 06/30/2026
Ikarian Capital, LLC 1.06 1,492,229 +0.0 03/31/2026

Funds

Funds PRQR
Name Stake (%) Shares Change (%) Date
abrdn World Healthcare 4.47 6,307,646 +0.0 07/31/2026
abrdn Life Sciences Investors 1.86 2,624,861 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?